MPN

United Kingdom Data Center Market Investment Report 2023-2028: Multi-Billion Opportunities Across 197 Existing Facilities and 30 Upcoming Facilities

Retrieved on: 
Monday, July 17, 2023

DUBLIN, July 17, 2023 /PRNewswire/ -- The "United Kingdom Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 17, 2023 /PRNewswire/ -- The "United Kingdom Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The UK data center market size is expected to reach a value of $10.18 billion by 2028 from $8.65 billion in 2022, growing at a CAGR of 2.8%
    This report analyses the UK data center market share.
  • The UK major data center construction locations include Greater London, Greater Manchester, and Berkshire are the major locations for data center construction.
  • In 2022, the UK Data Center Market witnessed investments from major companies such as Kao Data, Ark Data Centres, Echelon Data Centres, Colt Data Center Services, CyrusOne, Datum Datacentres, Global Switch, VIRTUS Data Centres, Vantage Data Centers, and others.

United Kingdom Data Center Market Investment Report 2023-2028: Lucrative Opportunities in IT, Electrical, Mechanical Infrastructure, General Construction, and Tier Standards - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 13, 2023

The "United Kingdom Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United Kingdom Data Center Market - Investment Analysis & Growth Opportunities 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • It elaboratively analyses the existing and upcoming facilities and investments in IT, electrical, mechanical infrastructure, general construction, and tier standards.
  • The UK major data center construction locations include Greater London, Greater Manchester, and Berkshire are the major locations for data center construction.
  • In 2022, the UK Data Center Market witnessed investments from major companies such as Kao Data, Ark Data Centres, Echelon Data Centres, Colt Data Center Services, CyrusOne, Datum Datacentres, Global Switch, VIRTUS Data Centres, Vantage Data Centers, and others.

New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera

Retrieved on: 
Friday, June 30, 2023

This study, which was conducted in China, demonstrated the efficacy and tolerability of ropeginterferon alfa-2b using an alternate dosing regimen that has a higher starting dose and a more rapid dose titration as compared to current U.S. label dosing.

Key Points: 
  • This study, which was conducted in China, demonstrated the efficacy and tolerability of ropeginterferon alfa-2b using an alternate dosing regimen that has a higher starting dose and a more rapid dose titration as compared to current U.S. label dosing.
  • The publication, titled “A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera,” was published in Experimental Hematology & Oncology and co-authored by PharmaEssentia researchers.
  • PV is the most common myeloproliferative neoplasm (MPN) and a long-term, potentially life-threatening disease with limited approved treatment options.
  • Long-term treatment and follow-up of the patients in the study are planned to assess progression-free and overall survival.

5G Consortium Continues to Expand Adding New Members to Private Mobile Networks Ecosystem

Retrieved on: 
Wednesday, June 28, 2023

ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Athonet , a global leader in private network technology, approved new members to the 5G Consortium , a vendor ecosystem of companies and organizations to promote the deployment of private mobile networks.

Key Points: 
  • ALPHARETTA, Ga., June 28, 2023 /PRNewswire/ -- Athonet , a global leader in private network technology, approved new members to the 5G Consortium , a vendor ecosystem of companies and organizations to promote the deployment of private mobile networks.
  • The goal of the 5G Consortium is to mutually promote an ecosystem of products and services that support LTE, 5G and CBRS private network deployments; collaborate in marketing the consortium; and conduct testing between products to ensure solutions are interoperable with each other and within the private LTE and 5G cellular environment.
  • New members to the 5G Consortium bring additional global expertise as well as hardware and services capabilities.
  • We are excited to join the 5G Consortium where we will expand our reach and develop new collaborations with 5G Consortium members to offer trusted technology and service solutions to maximize the benefits of private networks for new industries.

Arqit: Accelerating 5G Open-RAN to meet the UK's future communications needs to develop new telecoms networks for the UK

Retrieved on: 
Wednesday, June 14, 2023

The aim of Secure 5G is to reduce costs, while accelerating the pace of innovation, enabling faster roll-out of services and more secure communications via a UK sovereign supply chain.

Key Points: 
  • The aim of Secure 5G is to reduce costs, while accelerating the pace of innovation, enabling faster roll-out of services and more secure communications via a UK sovereign supply chain.
  • The Secure 5G project will pave the way for more secure and competitive telecoms networks in the UK, benefiting industries across the board.
  • Secure 5G will accelerate the pace of innovation and further enable secure communications via a UK sovereign supply chain.
  • The technology developed by the consortium will accelerate Open-RAN through a powerful, secure and scalable 5G solution to meet the UK's future communications needs.

Arqit: Accelerating 5G Open-RAN to meet the UK's future communications needs to develop new telecoms networks for the UK

Retrieved on: 
Wednesday, June 14, 2023

The aim of Secure 5G is to reduce costs, while accelerating the pace of innovation, enabling faster roll-out of services and more secure communications via a UK sovereign supply chain.

Key Points: 
  • The aim of Secure 5G is to reduce costs, while accelerating the pace of innovation, enabling faster roll-out of services and more secure communications via a UK sovereign supply chain.
  • The Secure 5G project will pave the way for more secure and competitive telecoms networks in the UK, benefiting industries across the board.
  • Secure 5G will accelerate the pace of innovation and further enable secure communications via a UK sovereign supply chain.
  • The technology developed by the consortium will accelerate Open-RAN through a powerful, secure and scalable 5G solution to meet the UK's future communications needs.

Ajax Therapeutics Appoints Eric S. Fischer, PhD, to Scientific Advisory Board

Retrieved on: 
Wednesday, May 24, 2023

Ajax Therapeutics, Inc. , a biopharmaceutical company applying computational chemistry and structure-based technologies to develop first-in-class and best-in-class JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Eric S. Fischer, PhD, to the Company’s Scientific Advisory Board (SAB).

Key Points: 
  • Ajax Therapeutics, Inc. , a biopharmaceutical company applying computational chemistry and structure-based technologies to develop first-in-class and best-in-class JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Eric S. Fischer, PhD, to the Company’s Scientific Advisory Board (SAB).
  • Dr. Fischer is a global leader in targeted protein degradation with appointments at Dana-Farber Cancer Institute (Dana-Farber) and Harvard Medical School.
  • He is a co-founder of Civetta Therapeutics, Neomorph, Inc. and Proximity Therapeutics.
  • Dr. Fischer completed his undergraduate training at the Universities of Hamburg and Basel and his doctoral training at the Friedrich Miescher Institute for Biomedical Research.

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress

Retrieved on: 
Thursday, May 11, 2023

These data reinforce the potential emerging role of targeting both CDK8/19 and JAK1/2 in myeloproliferative neoplasms.

Key Points: 
  • These data reinforce the potential emerging role of targeting both CDK8/19 and JAK1/2 in myeloproliferative neoplasms.
  • Results from patients dosed up to 110 mg have shown a favorable safety profile of RVU120.
  • At the data cut-off of February 28, 2023, 22 pts have been enrolled, and 10 out of 19 evaluable patients showed clinical benefit: 1 pt.
  • The data warrant further exploration of RVU120 in AML and HR-MDS, and enrollment is ongoing at 135 mg.

Continued growth in mobile postpaid and Internet subscriptions in Q1 2023

Retrieved on: 
Wednesday, May 10, 2023

Continued commercial momentum in Q1 2023: net increase of +48,000 mobile postpaid1) subscriptions in the mobile segment and +7,200 Internet subscriptions in the broadband segment.

Key Points: 
  • Continued commercial momentum in Q1 2023: net increase of +48,000 mobile postpaid1) subscriptions in the mobile segment and +7,200 Internet subscriptions in the broadband segment.
  • Sustained growth in fixed-mobile convergence (FMC): as of March 31, 2023, 57.6% of fixed broadband customers were also using a mobile postpaid plan (+0.9% YoY).
  • Sunrise continued to invest heavily in infrastructure and product innovations in Q1 2023 with CHF 137.8 million.
  • This resulted in a net increase of +48,000 mobile postpaid1) subscriptions as well as +7,200 Internet and +300 (Enhanced Video) TV subscriptions in Q1 2023.

Medigene AG presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers

Retrieved on: 
Monday, April 24, 2023

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reports final Phase I dose escalation results from first-in-human Study of HLA-A*02:01-restricted PRAME-specific T cell receptor engineered T cell (TCR-T) therapy (MDG1011) for high-risk myeloid and lymphoid neoplasms ( NCT03503968 ).

Key Points: 
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reports final Phase I dose escalation results from first-in-human Study of HLA-A*02:01-restricted PRAME-specific T cell receptor engineered T cell (TCR-T) therapy (MDG1011) for high-risk myeloid and lymphoid neoplasms ( NCT03503968 ).
  • Subsequently, nine patients with relapsed or refractory AML, MDS/MPN or MM received MDG1011 by single intravenous infusion after a lymphodepleting regimen.
  • Patients received MDG1011 at one of three escalating dose levels (DL): 0.1 (DL1), 1.0 (DL2) or 5.0 (DL3) million TCR-transduced T cells per kg body weight.
  • Immune monitoring of patients included quantification of PRAME levels in bone marrow (BM) and/or peripheral blood (PB) and pharmacokinetics of MDG1011 in PB.